scholarly journals Combining differential expression and differential coexpression analysis identifies optimal gene and gene set in cervical cancer

2018 ◽  
Vol 14 (1) ◽  
pp. 201 ◽  
Author(s):  
Hong-Bing Cai ◽  
Sheng-Quan Fang ◽  
Min Gao ◽  
Shi-Lu Xiong ◽  
Hai-Yan Chen ◽  
...  
2009 ◽  
pp. 145-156 ◽  
Author(s):  
GANG FANG ◽  
RUI KUANG ◽  
GAURAV PANDEY ◽  
MICHAEL STEINBACH ◽  
CHAD L. MYERS ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Lin Yuan ◽  
Chun-Hou Zheng ◽  
Jun-Feng Xia ◽  
De-Shuang Huang

More and more studies have shown that many complex diseases are contributed jointly by alterations of numerous genes. Genes often coordinate together as a functional biological pathway or network and are highly correlated. Differential coexpression analysis, as a more comprehensive technique to the differential expression analysis, was raised to research gene regulatory networks and biological pathways of phenotypic changes through measuring gene correlation changes between disease and normal conditions. In this paper, we propose a gene differential coexpression analysis algorithm in the level of gene sets and apply the algorithm to a publicly available type 2 diabetes (T2D) expression dataset. Firstly, we calculate coexpression biweight midcorrelation coefficients between all gene pairs. Then, we select informative correlation pairs using the “differential coexpression threshold” strategy. Finally, we identify the differential coexpression gene modules using maximum clique concept andk-clique algorithm. We apply the proposed differential coexpression analysis method on simulated data and T2D data. Two differential coexpression gene modules about T2D were detected, which should be useful for exploring the biological function of the related genes.


Author(s):  
Mari K. Halle ◽  
Marte Sødal ◽  
David Forsse ◽  
Hilde Engerud ◽  
Kathrine Woie ◽  
...  

Abstract Background Advanced cervical cancer carries a particularly poor prognosis, and few treatment options exist. Identification of effective molecular markers is vital to improve the individualisation of treatment. We investigated transcriptional data from cervical carcinomas related to patient survival and recurrence to identify potential molecular drivers for aggressive disease. Methods Primary tumour RNA-sequencing profiles from 20 patients with recurrence and 53 patients with cured disease were compared. Protein levels and prognostic impact for selected markers were identified by immunohistochemistry in a population-based patient cohort. Results Comparison of tumours relative to recurrence status revealed 121 differentially expressed genes. From this gene set, a 10-gene signature with high prognostic significance (p = 0.001) was identified and validated in an independent patient cohort (p = 0.004). Protein levels of two signature genes, HLA-DQB1 (n = 389) and LIMCH1 (LIM and calponin homology domain 1) (n = 410), were independent predictors of survival (hazard ratio 2.50, p = 0.007 for HLA-DQB1 and 3.19, p = 0.007 for LIMCH1) when adjusting for established prognostic markers. HLA-DQB1 protein expression associated with programmed death ligand 1 positivity (p < 0.001). In gene set enrichment analyses, HLA-DQB1high tumours associated with immune activation and response to interferon-γ (IFN-γ). Conclusions This study revealed a 10-gene signature with high prognostic power in cervical cancer. HLA-DQB1 and LIMCH1 are potential biomarkers guiding cervical cancer treatment.


Sign in / Sign up

Export Citation Format

Share Document